C1orf210

Across TCGA pan-cancer cohorts, C1orf210 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C1orf210 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C1orf210 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C1orf210 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where C1orf210 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.906	0.602	<.001	66	view →
CCRCC	OS	Quartile	All	0.936	0.651	.005	21	view →
LUAD	OS	Median	III,IV	0.840	0.166	.003	6	view →
HNSC	OS	Tertile	All	0.945	0.648	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C1orf210–PDAC (DFS)

Open the PDAC breakdown →